

Adaptor protein complexes and disease at a glance

Anneri Sanger, Jennifer Hirst, Alexandra K. Davies and Margaret S. Robinson*

ABSTRACT

Adaptor protein (AP) complexes are heterotetramers that select cargo for inclusion into transport vesicles. Five AP complexes (AP-1 to AP-5) have been described, each with a distinct localisation and function. Furthermore, patients with a range of disorders, particularly involving the nervous system, have now been identified with mutations in each of the AP complexes. In many cases this has been correlated with aberrantly localised membrane proteins. In this Cell Science at a Glance article and the accompanying poster, we summarize what is

known about the five AP complexes and discuss how this helps to explain the clinical features of the different genetic disorders.

KEY WORDS: Adaptor protein complex, Clathrin, Membrane traffic, Endocytosis, Golgi, Hereditary spastic paraplegia


Introduction

Nearly a third of the proteins encoded by the human genome are predicted to be integral membrane proteins, all of which have to get to the right part of the cell. There are several ways of moving membrane proteins from one subcellular compartment to another, but perhaps the most common way is to package them into coated vesicles. The coat is made up of protein complexes, which are recruited onto a particular membrane compartment where they shape the membrane into a vesicle and collect the vesicle cargo. After the vesicle buds, it sheds its coat and goes on to fuse with a different

Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.

*Author for correspondence (msr12@cam.ac.uk)

id M.S.R., 0000-0003-0631-0053



membrane compartment. COPI- and COPII-coated vesicles facilitate trafficking between the ER and the Golgi, while many of the post-Golgi trafficking pathways make use of adaptor protein (AP) complexes. The AP complexes are evolutionarily related to part of the COPI coat, and their function is to select cargo for inclusion into vesicles (Traub and Bonifacino, 2013; Robinson, 2015). Several genetic disorders have now been identified where the causative mutation is in an AP subunit. This results in membrane proteins failing to get packaged correctly into vesicles, so that they end up in the wrong part of the cell. In this article and the accompanying poster, we provide a brief overview of the AP complexes and how they are thought to work, and we discuss the disease-causing mutations that have been found in each of the complexes.

Structure and localisation of AP complexes

Five AP complexes have been identified. The first to be discovered were AP-1 and AP-2, which are abundant components of clathrin-coated vesicles (CCVs) (Zaremba and Keen, 1983; Pearse and Robinson, 1984; Keen, 1987). The two APs coordinate CCV formation by providing a link between the membrane and the clathrin scaffold. They also recruit accessory proteins to the CCV, some of which act as cargo-specific adaptors (Traub, 2009). AP-1 is associated with the trans-Golgi network (TGN) and early and/or recycling endosomes, whereas AP-2 is located at the plasma membrane (Robinson, 2015) (see poster). Both AP-1 and AP-2 are heterotetramers, consisting of two large (~100 kDa) subunits, γ and $\beta 1$ in the AP-1 complex, and α and $\beta 2$ in the AP-2 complex; a medium-sized (~50 kDa) μ subunit; and a small (~20 kDa) σ subunit (see poster). The N-terminal domains of the large subunits, together with the medium and small subunits, form a compact core, while the C-terminal domains of the large subunits form appendages that connect to the core by flexible linkers.

Two additional adaptor protein complexes, AP-3 and AP-4, were found in the 1990s on the basis of their homology to AP-1 and AP-2 (Robinson and Bonifacino, 2001). AP-3 is made up of δ , $\beta 3$, $\mu 3$ and $\sigma 3$ subunits, and AP-4 of ϵ , $\beta 4$, $\mu 4$ and $\sigma 4$ subunits. AP-3 is present on the same endosomes as AP-1, whereas AP-4 localises to the TGN (see poster). In 2011, a fifth AP complex was discovered, which localises to late endosomes. AP-5 had previously escaped detection because its subunits have little sequence similarity to those of the other APs (Hirst et al., 2011). In 2014, a sixth complex, TSET, was discovered (Hirst et al., 2014). TSET is associated with the plasma membrane, although it is slightly more closely related to the early-Golgi COPI complex than to the post-Golgi AP complexes. All seven of these complexes (the five APs, TSET and COPI) are ancient and present in most eukaryotes, although there are examples of secondary loss: for instance, TSET has been lost from animals and fungi.

Getting to the correct membrane

In order for the AP complexes to function, they need to be recruited onto the correct membrane. Three of the complexes, AP-1, AP-3 and AP-4, make use of the small GTPase ARF1, which also facilitates the recruitment of COPI. ARF1 is recruited onto the membrane first, coordinated by the exchange of GDP for GTP. The active GTP-bound ARF1 then recruits coat proteins and other effectors (Donaldson and Jackson, 2011). Structures have been solved for both COPI and AP-1 bound to activated ARF1, and the binding mechanisms are very similar, involving the two large subunits (Ren et al., 2013; Dodonova et al., 2015). However, binding to activated ARF1 is clearly not the only interaction that contributes to the recruitment of these coats, because COPI, AP-1, AP-3 and AP-4 all

have distinct subcellular localisations. The current view is that recruitment is by coincidence detection, with multiple medium-to-low affinity interactions ensuring that the coat is recruited onto the correct membrane (Kirchhausen et al., 2014).

AP-2 and AP-5 don't appear to use ARF1, but they both have a strong phosphoinositide requirement, making use of phosphatidylinositol 4,5-bisphosphate (PIP₂) and phosphatidylinositol 3-phosphate (PI3P), respectively (see poster). PIP₂ is found mainly on the plasma membrane, where AP-2 is recruited, and three of the AP-2 subunits have PIP₂-binding sites (Collins et al., 2002). AP-5 is closely associated with two other proteins, SPG11 (spatacsin) and SPG15 (spastizin, also known as ZFYVE26). SPG15 has a PI3P-binding FYVE domain, and treatment of cells with the PI3-kinase inhibitor wortmannin causes the AP-5–SPG11–SPG15 complex to become cytosolic rather than associated with late endosomes (Hirst et al., 2013). However, much of the PI3P in the cell is on early endosomes, providing further evidence for the coincidence detection hypothesis.

In addition to facilitating recruitment, the binding of AP-2 to PIP₂ and of AP-1 to ARF1 induce a conformational change, from a 'closed' to an 'open' conformation (Jackson et al., 2010; Ren et al., 2013; Kelly et al., 2014). Opening up the complex exposes binding sites for cargo and clathrin. These interactions further stabilise the open conformation, and help to nucleate the assembly of the coat (Mettlen and Danuser, 2014).

Selecting the correct cargo

Most cargo proteins interact with coats through short linear motifs in their cytoplasmic tails. There are two well-characterised cargo-binding sites on the APs, one for the tyrosine-based motif Yxx Φ (where Φ is a bulky hydrophobic residue), and one for the dileucine motif, [D/E]xxxL[L/I] (see poster). Yeast two-hybrid experiments, which can be used to investigate protein–protein interactions, were the first to show that the Yxx Φ motif binds to the AP medium subunits, specifically to the C-terminal 'μ homology domain' (MHD) (Ohno et al., 1995). Subsequent X-ray crystallography studies on AP-2 showed how the tyrosine and bulky hydrophobic residues fit into compatible pockets, which are inaccessible when the complex is in its closed conformation (Owen and Evans, 1998; Jackson et al., 2010). Membrane proteins that have Yxx Φ motifs in their cytosolic tails include intracellular sorting receptors for lysosomal hydrolases (e.g. cation-dependent and cation-independent mannose-6-phosphate receptors), endocytic receptors (e.g. the transferrin receptor), lysosomal membrane proteins (e.g. LAMP1 and LAMP2), and TGN-resident proteins [e.g. TGN38 (also known as TGOLN2) and furin] (Bonifacino and Traub, 2003).

The molecular basis for dileucine sorting was also first uncovered in yeast, in this case by using the three-hybrid system, which is a way of investigating three-way protein interactions. Two of the AP subunits act in concert to bind the motif: the small subunit, and one of the large subunits (Janvier et al., 2003; Doray et al., 2007). Structural studies on AP-2 showed that the two leucines are accommodated by hydrophobic pockets in the $\sigma 2$ subunit, while the acidic residue (D or E) sits on a positively charged patch provided by the α and $\sigma 2$ subunits (Kelly et al., 2008). Like the Yxx Φ motif, the dileucine motif is found in many different proteins, and can act as both an internalisation signal and an intracellular sorting signal (Bonifacino and Traub, 2003).

Making a vesicle

Clathrin-coated vesicle formation at the plasma membrane has been extensively studied, using methods ranging from live cell imaging to

in vitro reconstitution. It seems clear that the ability of clathrin to self-assemble into spherical cages is essential for shaping the membrane (Hinrichsen et al., 2006; Dannhauser and Ungewickell, 2012). The best-characterised clathrin-binding motif, found on AP-1 and AP-2, as well as on other clathrin-associated proteins, is the clathrin box, L Φ [D/E/N] Φ [D/E], where Φ is a bulky hydrophobic residue (Dell'Angelica et al., 1998). This motif is found in the β subunits of both AP-1 and AP-2, and interestingly also in the β subunit of AP-3, even though AP-3 is not enriched in CCVs (Dell'Angelica et al., 1998). The current view is that AP-3 is able to interact with clathrin (Peden et al., 2004), but that this interaction may not be essential for AP-3 function (Peden et al., 2002).

However, there is no evidence for any sort of interaction between clathrin and either AP-4 or AP-5, raising the question of how (or even if) they make vesicles. Studies on COPI and COPII, as well as on several clathrin-associated proteins, show that there are several ways to bend a membrane into a vesicle. Part of the COPII coat forms an outer cage that is superficially similar to the clathrin cage (Stagg et al., 2006), while COPI, together with bound ARF1, assembles on membranes into an inherently curved structure (Dodonova et al., 2015). Some of the proteins associated with CCVs have large hydrodynamic radii and are thought to bend membranes by molecular crowding (Stachowiak et al., 2012), while others may generate curvature by driving a wedge into a membrane (Ford et al., 2002). A key experiment will be to try to make AP-4- or AP-5-coated vesicles *in vitro*, using minimal components: e.g., AP-4, its accessory protein tepsin, and ARF1, or AP-5 together with SPG11 and SPG15. This should reveal whether and/or how AP-4 and AP-5 shape membranes.

Genetic disorders of AP subunits

If a mutation in a gene is non-lethal, then there is a good chance that it will turn up in the human population. Disease-causing mutations have now been found in all of the AP complexes, even in AP-1 and AP-2, which are essential for life in animals. The lack of any one subunit renders the entire complex non-functional (Robinson, 2015), so loss-of-function mutations in any subunit of a particular complex should have the same phenotype.

AP-1

Mice without any AP-1 die as embryos (Zizioli et al., 1999; Meyer et al., 2000), but mammals have three genes encoding the AP-1 small subunit, and loss of any one of them is non-lethal. Indeed, individuals with genetic disease have been identified with mutations in each of the three (see poster). The first of these mutations was discovered in a large-scale study on X-linked intellectual disability, where three families were found with truncating mutations in the *APIS2* gene, encoding σ 1B (Tarpey et al., 2006). Subsequent studies identified autosomal recessive mutations in both of the other σ 1 genes. Mutations in *APIS1* (σ 1A) affect many cell types and cause a unique syndrome called MEDNIK (an acronym for mental retardation, enteropathy, deafness, peripheral neuropathy, ichthyosis and keratoderma) (Montpetit et al., 2008). Mutations in *APIS3* (σ 1C) mainly affect the skin, causing an autoinflammatory condition called pustular psoriasis (Setta-Kaffetzi et al., 2014). There is also a mouse model for σ 1B deficiency (Glyvuk et al., 2010) (Box 1).

Why do mutations in the three genes cause such different phenotypes? Part of the explanation may be that they are expressed at different levels in different cell types. There is limited information about σ 1 protein expression, but in HeLa cells, σ 1A is the most abundant of the three, followed by σ 1C and σ 1B (Itzhak et al., 2016). In contrast, in mouse neurons, σ 1A is about twice as

Box 1. Mouse models.

A number of the AP subunit genes that are mutated in individuals with AP complex-associated genetic disease have been knocked out in mice, and in most cases the phenotypes are very similar (e.g. Glyvuk et al., 2010; Khundadze et al., 2019). There are also mouse knockouts of genes that have not (yet) been implicated in disease.

The AP-1 medium subunit is encoded by two genes in mammals: *AP1M1*, which is expressed ubiquitously and is essential for embryonic development (Meyer et al., 2000), and *AP1M2*, which is expressed only in epithelial cells, where it contributes to basolateral protein targeting (Fölsch et al., 1999; Guo et al., 2013). Mouse *AP1M2* knockouts are viable, although there is increased mortality in the first 8 weeks. In addition, the mice develop spontaneous chronic colitis and intestinal epithelial cell hyperplasia (Takahashi et al., 2011). This has been correlated with mistrafficking of certain cytokine receptors and E-cadherin, both of which are normally restricted to the basolateral cell surface (Hase et al., 2013).

Complete loss of AP-2 is early embryonic lethal (Mitsunari et al., 2005), but mice lacking the single-copy AP-2 β subunit gene *AP2B1* survive until birth but then die shortly afterwards, the only obvious abnormality being that they have a cleft palate (Li et al., 2010). The reason for their viability is that the β subunit of AP-1 is able to substitute. Many organisms share a common β 1/ β 2 subunit, and the duplication that gave rise to *AP1B1* and *AP2B1* occurred relatively recently (Dacks and Robinson, 2017); therefore, β 1 and β 2 are sufficiently similar that they can interact with each other's partners. Why loss of β 2 results in a cleft palate is less clear, but it could be related to effects on TGF- β receptor endocytosis (Li et al., 2010).

AP-3 has ubiquitously expressed and neuronal-specific genes not only for its β subunits, but also for its μ subunits. In mouse, knocking out the neuronal-specific medium subunit gene *AP3M2* produces a similar phenotype to knocking out *AP3B2*. In both cases, the mice have spontaneous epileptic seizures, correlated with a reduction in GABA transporters in synaptic vesicles (Nakatsu et al., 2004; Seong et al., 2005).

All three of these examples provide insights into human pathophysiology, and point towards candidate genes to be investigated in patients with similar clinical features.

abundant as σ 1B, while σ 1C is undetectable (Itzhak et al., 2017). Moreover, northern blotting and RT-PCR on mouse tissues indicate that σ 1A and σ 1B are more strongly expressed in brain than in other tissues, while expression of σ 1C is relatively weak in brain (Glyvuk et al., 2010). This may help to explain why mutations in σ 1A (*APIS1*) or σ 1B (*APIS2*) affect the nervous system, while mutations in σ 1C (*APIS3*) do not.

Another possibility is that the different σ 1 isoforms may have different cargo preferences. Several membrane proteins have been found to exhibit aberrant localisations or expression levels in cells that are deficient in one of the σ 1 genes, including Toll-like receptor 3 (TLR-3) in *APIS3*-knockdown macrophages (Setta-Kaffetzi et al., 2014), sortilin in adipocytes from *APIS2*-knockout mice (Baltes et al., 2014), and ATP7A in fibroblasts from a patient homozygous for a null mutation in *APIS1* (Martinelli et al., 2013).

The ATP7A phenotype is probably the best understood. ATP7A and ATP7B are copper-transporting ATPases that maintain copper homeostasis in mammalian cells, with ATP7A expressed ubiquitously and ATP7B expressed mainly in hepatocytes. Both proteins are localised at the TGN under control conditions, but are translocated to the plasma membrane in response to elevated copper levels (La Fontaine and Mercer, 2007). ATP7A and ATP7B have dileucine motifs and are packaged into CCVs in an AP-1-dependent manner (Hirst et al., 2012; Jain et al., 2015; Yi and Kaler, 2015), which helps to maintain their normal steady state localisation. Lack of ATP7A or ATP7B cause Menkes disease and Wilson disease,

respectively, both of which share some clinical features with MEDNIK syndrome (Martinelli et al., 2013). Thus, mislocalisation of copper-transporting ATPases can account for at least some of the symptoms of $\sigma 1A$ deficiency. What is less clear is whether $\sigma 1A$ has the highest affinity of all the $\sigma 1$ gene products for ATP7A and ATP7B, or whether it is simply more abundant than the other two in those tissues that are most affected by the disease.

AP-2

Two human genetic disorders involving AP-2 subunits have been described, both of which are caused by autosomal dominant missense mutations. The first is familial hypocalcaemic hypercalcaemia type 3 (FHH3), caused by a mutation in the single-copy small subunit gene, *AP2S1* (see poster). Multiple families have now been identified where a highly conserved arginine residue, R15, is mutated to a cysteine, a histidine or a leucine (Nesbit et al., 2013b). There are two other types of familial hypocalcaemic hypercalcaemia: FHH1, caused by mutations in the calcium-sensing G-protein-coupled receptor (GPCR) CaSR, and FHH2, caused by mutations in the α subunit of the G-protein that interacts with CaSR (Nesbit et al., 2013a). Thus, it seems likely that the missense mutations in *AP2S1* affect the trafficking of CaSR, a possibility supported by the finding that there is increased surface expression of the receptor in cells expressing mutated $\sigma 2$ (Nesbit et al., 2013b).

Interestingly, the crystal structure of AP-2 with bound peptides shows that the conserved R15 residue in $\sigma 2$ makes contact with the [D/E]xxxL[L/I] motif, specifically with the first residue, which is normally acidic (Kelly et al., 2008). Moreover, the cytosolic tail of CaSR contains two leucines in a row, leading to the suggestion that normally CaSR is internalised in a dileucine- and AP-2-dependent manner, but that this does not occur when R15 is mutated (Nesbit et al., 2013b). However, there are a few inconsistencies with this hypothesis. First, it has been shown that mutating R15 does not affect dileucine binding *in vitro* (Kelly et al., 2008), and second, the sequence in the CaSR cytoplasmic tail (RHQPLL) does not conform to a canonical dileucine motif, and there is no evidence that it contributes to the localisation of the protein. GPCRs are normally internalized via the cargo-selective adaptor β -arrestin, which binds to the $\beta 2$ appendage (Goodman et al., 1996; Keyel et al., 2008), so it is not clear what a mutation in the AP-2 small subunit would do. Moreover, internalization of GPCRs is usually a mechanism for inactivating them, so impaired internalization would be expected to activate rather than inactivate the receptor (Goodman et al., 1996). There is also the question of why this mutation appears to affect only a single cargo protein.

A more recent study helps to explain at least some of these discrepancies (Gorvin et al., 2018). The authors showed that sustained signalling by CaSR occurs from endosomes rather than from the plasma membrane, and they also reported that the mutation in $\sigma 2$ led to increased colocalisation between CaSR and clathrin in static structures (Gorvin et al., 2018). This suggests that in the cells of individuals with these particular mutations in $\sigma 2$, the receptor may be getting stuck in coated pits rather than failing to access them. Clearly, there is a lot more to unravel before we really understand the molecular basis for FHH3.

The second autosomal dominant missense mutation is in the AP-2 μ subunit (see poster) (Helbig et al., 2019), recently identified in a large-scale study on epilepsy, in which four out of 2624 affected individuals were found to have the same *de novo* variant. A single base C-to-T substitution causes a highly conserved arginine, R170, to be replaced by a tryptophan. This residue is just upstream from the MHD, and *in silico* modelling suggests that the R17W mutant may

be impaired in its ability to undergo the conformational change that is essential for cargo recognition, a possibility supported by the finding that the mutant only partially rescues transferrin uptake in $\mu 2$ -deficient cells. Precisely why the mutation causes epilepsy is less clear, but clathrin-mediated endocytosis plays a key role in synaptic vesicle retrieval in neurons. Moreover, *de novo* missense mutations in dynamin (DNM1), which facilitates the scission of CCVs, also cause epilepsy, albeit with a different clinical phenotype (EuroEPINOMICS-RES Consortium et al., 2014).

In addition to these relatively rare mutations in AP-2 subunits, there are much more common mutations that have been identified in cargo and machinery for the AP-2 pathway (see Box 2).

AP-3

Unlike AP-1 and AP-2, AP-3 is non-essential in animals. Recessive disease-causing mutations have been identified in three of the AP-3 subunits: the single-copy δ gene, *AP3D1*, and both of the $\beta 3$ genes, *AP3B1*, which is expressed ubiquitously, and *AP3B2*, which is neuronal-specific (Dell'Angelica et al., 1997; Simpson et al., 1997). Mutations in *AP3B1* cause Hermansky-Pudlak syndrome type 2, a multisystem disorder characterised by albinism, prolonged bleeding, immunodeficiency and pulmonary fibrosis (see poster) (Dell'Angelica et al., 1999). All of these abnormalities can be correlated with aberrant trafficking to lysosomes and lysosome-related organelles, such as melanosomes, platelet dense bodies and dendritic cell phagosomes (Dell'Angelica et al., 1999; Mantegazza et al., 2012). Mutations in

Box 2. Genetic disorders of cargo and accessory proteins.

In addition to mutations in adaptor proteins that affect cargo localisation, there are several examples of mutations in the cargo proteins themselves that cause them to be mislocalised. Probably the most famous of these is a mutation in the low-density lipoprotein (LDL) receptor, discovered by the Brown and Goldstein labs, that causes the receptor to remain on the cell surface instead of being internalised by clathrin-mediated endocytosis (Anderson et al., 1977). This results in almost as severe a case of familial hypercholesterolaemia as that found in patients with no LDL receptors on the cell surface at all. The Brown and Goldstein labs went on to show (not trivial in the mid-1980s) that the causative mutation was a tyrosine-to-cysteine substitution, leading to the discovery of the first internalization signal, FxNPxY (Davis et al., 1986; Chen et al., 1990). Ironically, this is not a sorting signal for AP complexes, but for cargo-selective adaptors with PTB domains, such as autosomal recessive hypercholesterolemia (ARH, also known as LDLRAP1), the clathrin adaptor disabled homolog 2 (DAB2), and the endocytic adaptor protein NUMB (Mishra et al., 2002a,b). Most of the LDL clearance occurs in the liver, where ARH is highly expressed, and mutations in ARH also cause hypercholesterolaemia (Garcia et al., 2001), as indicated by the protein name.

Another example of a mutation in a cargo protein that prevents it from interacting with adaptors is the premature truncation of the anion exchanger AE1 (also known as SLC4A1), which leads to autosomal-dominant distal renal tubular acidosis. The truncation removes a Yxx Φ motif, which is essential for its basolateral localisation, most likely by interacting with AP-1 (Devonald et al., 2003). However, disease-causing mutations in membrane proteins don't necessarily have to remove sorting signals; they could also introduce new sorting signals. A recent study identified a new type of genetic disorder: the 'dileucineopathies'. Single-base substitutions were found to create dileucine motifs and cause membrane proteins that normally reside mainly on the plasma membrane to redistribute to endosomes (Meyer et al., 2018). In the case of the glucose transporter GLUT1 (also known as SLC2A1), this was shown to cause impaired glucose transport across the blood-brain barrier, resulting in intellectual disability and seizures (Meyer et al., 2018).

AP3D1 cause a similar phenotype, but with neurological problems as well, including neurodevelopmental delay, impaired hearing and severe seizures (see poster) (Ammann et al., 2016). There are also individuals with genetic disorders associated with mutations in *AP3B2*, who have the neurological symptoms only (see poster) (Assoum et al., 2016). These observations are consistent with the expression patterns of the three genes.

Cell biological studies have shown that lack of AP-3 causes increased surface expression of several lysosomal membrane proteins (Dell'Angelica et al., 1999), as well as missorting of the melanosomal proteins tyrosinase and OCA2 (Huizing et al., 2001; Theos et al., 2005; Sitaram et al., 2012). However, none of these proteins are completely mislocalised, seemingly because other AP complexes contribute to their steady-state distribution. The lysosomal membrane proteins all have YxxΦ and/or dileucine motifs and are efficiently retrieved by AP-2 and clathrin when they appear on the cell surface (Janvier and Bonifacino, 2005). Similarly, the melanosomal protein tyrosinase, which has both a YxxΦ and a dileucine motif, shows colocalisation with both AP-1 and AP-3, and can be sorted by either one (Theos et al., 2005). The cytomegalovirus glycoprotein gp48, which has a dileucine motif, is another example of a cargo protein that can be sorted by either AP-1 or AP-3 (Reusch et al., 2001). These findings may help to explain why AP-3 deficiency in humans is non-lethal.

AP-4

Patients with autosomal recessive mutations in any of the four AP-4 subunits present with severe intellectual disability and developmental delay, as well as progressive weakness and spasticity of the legs, i.e., spastic paraplegia (see poster) (Verkerk et al., 2009; Abou Jamra et al., 2011). Some of these patients had originally been misdiagnosed with cerebral palsy, suggesting that mutations in AP-4 may be more common than previously thought (Ebrahimi-Fakhari et al., 2018). There are also AP-4 knockout mice, which have a much milder phenotype than human patients (Matsuda et al., 2008), possibly because of the progressive nature of the illness. However, abnormalities were observed in the neurons of these mice, with AMPA receptor-containing autophagosomes accumulating in axons (Matsuda et al., 2008). This is consistent with the patient studies, because spastic paraplegias are caused by defects in the long axons of motor neurons (Blackstone et al., 2011).

Three independent studies have recently demonstrated that loss of AP-4 impairs the transport of the core autophagy protein ATG9A from the TGN to peripheral sites, which leads to dysregulation of autophagy (Mattera et al., 2017; Davies et al., 2018; De Pace et al., 2018; Ivankovic et al., 2019). This occurs in diverse cell types, including patient-derived fibroblasts and primary neurons from AP-4 knockout mice, suggesting that ATG9A trafficking is a ubiquitous function of AP-4. Defective autophagy is implicated in the aetiology of many neurodegenerative diseases (Menzies et al., 2017) and neuronal-specific loss of Atg9a in mice causes severe neurological phenotypes (Yamaguchi et al., 2018). Thus, it seems likely that missorting of ATG9A contributes, at least in part, to the neuropathology observed in AP-4-deficient patients.

Two proteins of unknown function, SERINC1 and SERINC3, colocalise with ATG9A in AP-4-dependent vesicles and are also mislocalised in AP-4-deficient cells (Davies et al., 2018). Other proteins reported to be sorted by AP-4 include amyloid precursor protein (APP) (Burgos et al., 2010) and transmembrane AMPA receptor regulatory proteins, or TARPs (Matsuda et al., 2008). Both APP and ATG9A have a tyrosine-based sorting signal, YxxΦE, which preferentially binds to subunit μ4 rather than to μ1, μ2 or μ3

(Burgos et al., 2010; Mattera et al., 2017). However, the other proteins that are thought to be sorted by AP-4 do not have a YxxΦE motif. Further mechanistic studies are required to understand cargo recognition by AP-4, and to assess the possible contribution of proposed AP-4 cargo proteins to disease caused by AP-4 deficiency.

AP-5

Disease-causing mutations in humans have so far only been identified for the AP-5 ζ subunit, encoded by *AP5Z1* (Słabicki et al., 2010; Hirst et al., 2016). Patients with homozygous or compound heterozygous mutations in this gene present with spastic paraplegia and other neurological abnormalities (see poster). Mutations in the AP-5-associated proteins SPG11 and SPG15 are more common, and the phenotype is similar for all three disorders, with spastic paraplegia accompanied by cognitive impairment and thin corpus callosum (viewed by MRI imaging of the brain) (Słabicki et al., 2010; Hirst et al., 2016; Pensato et al., 2014).

Fibroblasts from patients with mutations in *AP5Z1*, SPG11 or SPG15 accumulate aberrant endolysosomes (Hirst et al., 2015), similar to the fibroblasts of patients with lysosomal storage diseases, and accumulations of these organelles in axons may be the reason behind the neurological phenotype. Our recent search for AP-5 cargo proteins, carried out by identifying membrane proteins that are mislocalised in *AP5Z1*-knockout HeLa cells, suggests that the function of AP-5 is to retrieve a number of proteins from late endosomes and recycle them back to the Golgi complex (Hirst et al., 2018). These proteins may interact indirectly with AP-5 by binding to the transmembrane sorting receptor sortilin (Hirst et al., 2018). But whatever the mechanism for cargo recognition by AP-5, it seems unlikely that it involves canonical YxxΦ or dileucine motifs, because the sequences of the AP-5 subunits are so divergent from those of the other APs.

Perspectives

The first description of an AP complex was forty years ago, when CCV components of ~100 kD and ~50 kD were shown to promote clathrin assembly *in vitro*, hence the name AP, which was originally an acronym for assembly polypeptides (Keen et al., 1979). Since then, there have been many studies on the AP complexes, identifying all the different family members and finding out what they do. Because there has been so much basic cell biology on the five APs, in some cases, we have at least a partial understanding of why a particular mutation leads to a particular disease. However, in other cases, the mechanistic basis for the pathology is unclear. A more thorough understanding of the workings of all of the AP complexes will help us to understand the aetiology of the various diseases, and could eventually lead to the development of new treatments. Conversely, by finding out more about the consequences of AP deficiency in individuals with AP complex-associated genetic disease, we will be able to learn more about the cellular functions of the five AP complexes in all eukaryotes.

Acknowledgements

We thank both present and past members of the Robinson lab for their input.

Competing interests

The authors declare no competing or financial interests.

Funding

Work in the Robinson lab is funded by the Wellcome Trust (086598 and 214272).

Cell science at a glance

A high-resolution version of the poster and individual poster panels are available for downloading at <http://jcs.biologists.org/lookup/doi/10.1242/jcs.222992.supplemental>.

References

- Abou Jamra, R., Philippe, O., Raas-Rothschild, A., Eck, S. H., Graf, E., Buchert, R., Borck, G., Ekici, A., Brockschmidt, F. F., Nöthen, M. M. et al. (2011). Adaptor protein complex 4 deficiency causes severe autosomal-recessive intellectual disability, progressive spastic paraplegia, shy character, and short stature. *Am. J. Hum. Genet.* **88**, 788-795. doi:10.1016/j.ajhg.2011.04.019
- Ammann, S., Schulz, A., Krageloh-Mann, I., Dieckmann, N. M. G., Niethammer, K., Fuchs, S., Eckl, K. M., Plank, R., Werner, R., Altmüller, J. et al. (2016). Mutations in AP3D1 associated with immunodeficiency and seizures define a new type of Hermansky-Pudlak syndrome. *Blood* **127**, 997-1006. doi:10.1182/blood-2015-09-671636
- Anderson, R. G. W., Goldstein, J. L. and Brown, M. S. (1977). A mutation that impairs the ability of lipoprotein receptors to localise in coated pits on the cell surface of human fibroblasts. *Nature* **270**, 695-699. doi:10.1038/270695a0
- Assoum, M., Philippe, C., Isidor, B., Perrin, L., Makrythanasis, P., Sondheimer, N., Paris, C., Douglas, J., Lesca, G., Antonarakis, S. et al. (2016). Autosomal-recessive mutations in AP3B2, adaptor-related protein complex 3 beta 2 subunit, cause an early-onset epileptic encephalopathy with optic atrophy. *Am. J. Hum. Genet.* **99**, 1368-1376. doi:10.1016/j.ajhg.2016.10.009
- Baltes, J., Larsen, J. V., Radhakrishnan, K., Geumann, C., Kratzke, M., Petersen, C. M. and Schu, P. (2014). σ 1B adaptin regulates adipogenesis by mediating the sorting of sortilin in adipose tissue. *J. Cell Sci.* **127**, 3477-3487. doi:10.1242/jcs.146886
- Blackstone, C., O'Kane, C. J. and Reid, E. (2011). Hereditary spastic paraplegias: membrane traffic and the motor pathway. *Nat. Rev. Neurosci.* **12**, 31-42. doi:10.1038/nrn2946
- Bonifacino, J. S. and Traub, L. M. (2003). Signals for sorting of transmembrane proteins to endosomes and lysosomes. *Ann. Rev. Biochem.* **72**, 395-447. doi:10.1146/annurev.biochem.72.121801.161800
- Burgos, P. V., Mardones, G. A., Rojas, A. L., daSilva, L. L. P., Prabhu, Y., Hurley, J. H. and Bonifacino, J. S. (2010). Sorting of the Alzheimer's disease amyloid precursor protein mediated by the AP-4 complex. *Dev. Cell* **18**, 425-436. doi:10.1016/j.devcel.2010.01.015
- Chen, W. J., Goldstein, J. L. and Brown, M. S. (1990). NPXY, a sequence often found in cytoplasmic tails, is required for coated pit-mediated internalization of the low density lipoprotein receptor. *J. Biol. Chem.* **265**, 3116-3123.
- Collins, B. M., McCoy, A. J., Kent, H. M., Evans, P. R. and Owen, D. J. (2002). Molecular architecture and functional model of the endocytic AP2 complex. *Cell* **109**, 523-535. doi:10.1016/S0092-8674(02)00735-3
- Dacks, J. B. and Robinson, M. S. (2017). Outerwear through the ages: evolutionary cell biology of vesicle coats. *Curr. Opin. Cell Biol.* **47**, 108-116. doi:10.1016/j.cob.2017.04.001
- Dannhauser, P. N. and Ungewickell, E. J. (2012). Reconstitution of clathrin-coated bud and vesicle formation with minimal components. *Nat. Cell Biol.* **14**, 634-639. doi:10.1038/ncb2478
- Davies, A. K., Itzhak, D. N., Edgar, J. R., Archuleta, T. L., Hirst, J., Jackson, L. P., Robinson, M. S. and Borner, G. H. H. (2018). AP-4 vesicles contribute to spatial control of autophagy via RUSC-dependent peripheral delivery of ATG9A. *Nat. Commun.* **9**, 3958. doi:10.1038/s41467-018-06172-7
- Davis, C. G., Lehrman, M. A., Russell, D. W., Anderson, R. G. W., Brown, M. S. and Goldstein, J. L. (1986). The J. D. mutation in familial hypercholesterolemia: amino acid substitution in cytoplasmic domain impedes internalization of LDL receptors. *Cell* **45**, 15-24. doi:10.1016/0092-8674(86)90533-7
- De Pace, R., Skirzewski, M., Damm, M., Mattern, R., Mercurio, J., Foster, A. M., Cuitino, L., Jarnik, M., Hoffmann, V., Morris, H. D. et al. (2018). Altered distribution of ATG9A and accumulation of axonal aggregates in neurons from a mouse model of AP-4 deficiency syndrome. *PLoS Genet.* **14**, e1007363. doi:10.1371/journal.pgen.1007363
- Dell'Angelica, E. C., Ooi, C. E. and Bonifacino, J. S. (1997). β 3A-adaptin, a subunit of the adaptor-like complex AP-3. *J. Biol. Chem.* **272**, 15078-15084. doi:10.1074/jbc.272.24.15078
- Dell'Angelica, E. C., Klumperman, J., Stoorvogel, W. and Bonifacino, J. S. (1998). Association of the AP-3 complex with clathrin. *Science* **280**, 431-434. doi:10.1126/science.280.5362.431
- Dell'Angelica, E. C., Shotelersuk, V., Aguilar, R. C., Gahl, W. A. and Bonifacino, J. S. (1999). Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the β 3A subunit of the AP-3 adaptor. *Mol. Cell* **3**, 11-21. doi:10.1016/S1097-2765(00)80170-7
- Devonald, M. A. J., Smith, A. N., Poon, J. P., Ihrke, G. and Karet, F. E. (2003). Nonpolarized targeting of AE1 causes autosomal dominant distal renal tubular acidosis. *Nat. Genet.* **33**, 125-127. doi:10.1038/ng1082
- Dodonova, S. O., Diestelkoetter-Bachert, P., von Appen, A., Hagen, W. J. H., Beck, R., Beck, M., Wieland, F. and Briggs, J. A. G. (2015). A structure of the COPI coat and the role of coat proteins in membrane vesicle assembly. *Science* **349**, 195-198. doi:10.1126/science.aab1121
- Donaldson, J. G. and Jackson, C. L. (2011). Arf family G proteins and their regulators: roles in membrane transport, development and disease. *Nat. Rev. Mol. Cell Biol.* **12**, 362-375. doi:10.1038/nrm3117
- Doray, B., Lee, I., Knisely, J., Bu, G. and Kornfeld, S. (2007). The γ / σ 1 and α / σ 2 hemicomplexes of clathrin adaptors AP-1 and AP-2 harbor the dileucine recognition site. *J. Cell Biol.* **18**, 1887-1896. doi:10.1091/mbc.e07-01-0012
- Ebrahimi-Fakhari, D., Cheng, C., Dies, K., Diplock, A., Pier, D. B., Ryan, C. S., Lanpher, B. C., Hirst, J., Chung, W. K., Sahin, M. et al. and CureSPG47. (2018). Clinical and genetic characterization of AP4B1-associated SPG47. *Am. J. Med. Genet. A.* **17**, 311-318. doi:10.1002/ajmg.a.38561
- EuroEPINOMICS-RES Consortium, Epilepsy Phenome/Genome Project and Epi4K Consortium. (2014). De novo mutations in synaptic transmission genes including *DNM1* cause epileptic encephalopathies. *Am. J. Hum. Genet.* **95**, 360-370. doi:10.1016/j.ajhg.2014.08.013
- Fölsch, H., Ohno, H., Bonifacino, J. S. and Mellman, I. (1999). A novel clathrin adaptor complex mediates basolateral targeting in polarized epithelial cells. *Cell* **99**, 189-198. doi:10.1016/S0092-8674(00)81650-5
- Ford, M. G. J., Mills, I. G., Peter, B. J., Vallis, Y., Praefcke, G. J. K., Evans, P. R. and McMahon, H. T. (2002). Curvature of clathrin-coated pits driven by epsin. *Nature* **419**, 361-366. doi:10.1038/nature01020
- Garcia, C. K., Wilund, K., Arca, M., Zuliani, G., Fellin, R., Maioli, M., Calandra, S., Bertolini, S., Cossu, F., Grishin, N. et al. (2001). Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. *Science* **292**, 1394-1398. doi:10.1126/science.1060458
- Glyvyuk, N., Tsytsyura, Y., Geumann, C., D'Hooge, R., Hüve, J., Kratzke, M., Baltes, J., Böning, D., Klingauf, J. and Schu, P. (2010). AP-1/ σ 1B-adaptin mediates endosomal synaptic vesicle recycling, learning and memory. *EMBO J.* **29**, 1318-1330. doi:10.1038/emboj.2010.15
- Goodman, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H. and Benovic, J. L. (1996). β -arrestin acts as a clathrin adaptor in endocytosis of the β 2-adrenergic receptor. *Nature* **383**, 447-450. doi:10.1038/383447a0
- Gorvin, C. M., Rogers, A., Hastoy, B., Tarasov, A. I., Frost, M., Sposini, S., Inoue, A., Whyte, M. P., Rorsman, P., Hanyaloglu, A. C. et al. (2018). AP2 σ mutations impair calcium-sensing receptor trafficking and signaling, and show an endosomal pathway to spatially direct G-protein selectivity. *Cell Rep.* **22**, 1054-1066. doi:10.1016/j.celrep.2017.12.089
- Guo, X., Mattera, R., Ren, X., Chen, Y., Retamal, C., González, A. and Bonifacino, J. S. (2013). The adaptor protein-1 μ 1B subunit expands the repertoire of basolateral sorting signal recognition in epithelial cells. *Dev. Cell* **27**, 353-366. doi:10.1016/j.devcel.2013.10.006
- Hase, K., Nakatsu, F., Ohmae, M., Sugihara, K., Shioda, N., Takahashi, D., Obata, Y., Furusawa, Y., Fujimura, Y., Yamashita, T. et al. (2013). AP-1B-mediated protein sorting regulates polarity and proliferation of intestinal epithelial cells in mice. *Gastroenterology* **145**, 625-635. doi:10.1053/j.gastro.2013.05.013
- Helbig, I., Lopez-Hernandez, T., Shor, O., Galer, P., Ganesan, S., Pendziwiat, M., Rademacher, A., Ellis, C. A., Hümpfer, N., Schwarz, N. et al. (2019). A recurrent missense variant in AP2M1 impairs clathrin-mediated endocytosis and causes developmental and epileptic encephalopathy. *Am. J. Hum. Genet.* **104**, 1060-1072. doi:10.1016/j.ajhg.2019.04.001
- Hinrichsen, L., Meyerholz, A., Groos, S. and Ungewickell, E. J. (2006). Bending a membrane: how clathrin affects budding. *Proc. Natl. Acad. Sci. USA* **103**, 8715-8720. doi:10.1073/pnas.0600312103
- Hirst, J., Barlow, L. D., Francisco, G. C., Sahlender, D. A., Seaman, M. N. J., Dacks, J. B. and Robinson, M. S. (2011). The fifth adaptor protein complex. *PLoS Biol.* **9**, e1001170. doi:10.1371/journal.pbio.1001170
- Hirst, J., Borner, G. H. H., Antrobus, R., Peden, A. A., Hodson, N. A., Sahlender, D. A. and Robinson, M. S. (2012). Distinct and overlapping roles for AP-1 and GGAs revealed by the "knocksideways" system. *Curr. Biol.* **22**, 1711-1716. doi:10.1016/j.cub.2012.07.012
- Hirst, J., Borner, G. H. H., Edgar, J., Hein, M. Y., Mann, M., Buchholz, F., Antrobus, R. and Robinson, M. S. (2013). Interaction between AP-5 and the hereditary spastic paraplegia proteins SPG11 and SPG15. *Mol. Biol. Cell* **24**, 2558-2569. doi:10.1091/mbc.e13-03-0170
- Hirst, J., Schlacht, A., Norcott, J. P., Traynor, D., Bloomfield, G., Antrobus, R., Kay, R. R., Dacks, J. B. and Robinson, M. S. (2014). Characterization of TSET, an ancient and widespread membrane trafficking complex. *eLife* **3**, e02866. doi:10.7554/eLife.02866
- Hirst, J., Edgar, J. R., Esteves, T., Darios, F., Madeo, M., Chang, J., Roda, R. H., Dürr, A., Anheim, M., Gellera, C. et al. (2015). Loss of AP-5 results in accumulation of aberrant endolysosomes: defining a new type of lysosomal storage disease. *Hum. Mol. Genet.* **24**, 4984-4996. doi:10.1093/hmg/ddv220
- Hirst, J., Madeo, M., Smets, K., Edgar, J. R., Schols, L., Li, J., Yarrow, A., Deconinck, T., Baets, J., Van Aken, E. et al. (2016). Complicated spastic paraplegia in patients with AP5Z1 mutations (SPG48). *Neurol. Genet.* **2**, e98. doi:10.1212/NXG.0000000000000098
- Hirst, J., Itzhak, D. N., Antrobus, R., Borner, G. H. H. and Robinson, M. S. (2018). Role of the AP-5 adaptor protein complex in late endosome-to-Golgi retrieval. *PLoS Biol.* **16**, e2004411. doi:10.1371/journal.pbio.2004411
- Huizing, M., Sarangarajan, R., Strovel, E., Zhao, Y., Gahl, W. A. and Boissy, R. E. (2001). AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. *Mol. Biol. Cell* **12**, 2075-2085. doi:10.1091/mbc.12.7.2075

- Itzhak, D. N., Tyanova, S., Cox, J. and Borner, G. H. H.** (2016). Global, quantitative and dynamic mapping of protein subcellular localization. *eLife* **5**, e16950. doi:10.7554/eLife.16950
- Itzhak, D. N., Colin Davies, C., Tyanova, S., Mishra, A., Williamson, J., Antrobus, R., Cox, J., Weekes, M. P. and Borner, G. H. H.** (2017). A mass spectrometry-based approach for mapping protein subcellular localization reveals the spatial proteome of mouse primary neurons. *Cell Rep.* **20**, 2706-2718. doi:10.1016/j.celrep.2017.08.063
- Ivankovic, D., Drew, J., Lesept, F., White, I. J., López-Doménech, G., Tooze, S. A. and Kittler, J. T.** (2019). Axonal autophagosome maturation defect through failure of ATG9A sorting underpins pathology in AP-4 deficiency syndrome. *Autophagy*, doi:10.1080/15548627.2019.1615302. doi:10.1080/15548627.2019.1615302
- Jackson, L. P., Kelly, B. T., McCoy, A. J., Gaffry, T., James, L. C., Collins, B. M., Höning, S., Evans, P. R. and Owen, D. J.** (2010). A large-scale conformational change couples membrane recruitment to cargo binding in the AP2 clathrin adaptor complex. *Cell* **141**, 1220-1229. doi:10.1016/j.cell.2010.05.006
- Jain, S., Farias, G. G. and Bonifacino, J. S.** (2015). Polarized sorting of the copper transporter ATP7B in neurons mediated by recognition of a dileucine signal by AP-1. *Mol. Biol. Cell* **26**, 218-228. doi:10.1091/mbc.E14-07-1177
- Janvier, K. and Bonifacino, J. S.** (2005). Role of the endocytic machinery in the sorting of lysosome-associated membrane proteins. *Mol. Biol. Cell* **16**, 4231-4242. doi:10.1091/mbc.e05-03-0213
- Janvier, K., Kato, Y., Boehm, M., Rose, J. R., Martina, J. A., Kim, B.-Y., Venkatesan, S. and Bonifacino, J. S.** (2003). Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 γ - σ 1 and AP-3 δ - σ 3 hemicomplexes. *J. Cell Biol.* **163**, 1281-1290. doi:10.1083/jcb.200307157
- Keen, J. H.** (1987). Clathrin assembly proteins: affinity purification and a model for coat assembly. *J. Cell Biol.* **105**, 1989-1998. doi:10.1083/jcb.105.5.1989
- Keen, J. H., Willingham, M. C. and Pastan, I. H.** (1979). Clathrin-coated vesicles: isolation, dissociation and factor-dependent reassociation of clathrin baskets. *Cell* **16**, 303-312. doi:10.1016/0092-8674(79)90007-2
- Kelly, B. T., McCoy, A. J., Späte, K., Miller, S. E., Evans, P. R., Höning, S. and Owen, D. J.** (2008). A structural explanation for the binding of endocytic dileucine motifs by the AP2 complex. *Nature* **456**, 976-979. doi:10.1038/nature07422
- Kelly, B. T., Graham, S. C., Liska, N., Dannhauser, P., Höning, S., Ungewickell, E. J. and Owen, D. J.** (2014). Clathrin adaptors. AP2 controls clathrin polymerization with a membrane-activated switch. *Science* **345**, 459-463. doi:10.1126/science.1254836
- Keyel, P. A., Thieman, J. R., Roth, R., Erkan, E., Everett, E. T., Watkins, S. C., Heuser, J. E. and Traub, L. M.** (2008). The AP-2 adaptor β 2 appendage scaffolds alternate cargo endocytosis. *Mol. Biol. Cell* **19**, 5309-5326. doi:10.1091/mbc.e08-07-0712
- Khundadze, M., Ribaud, F., Hussain, A., Rosentreter, J., Nietzsche, S., Thelen, M., Winter, D., Hoffmann, B., Afzal, M. A., Hermann, T. et al.** (2019). A mouse model for SPG48 reveals a block of autophagic flux upon disruption of adaptor protein complex five. *Neurobiol. Dis.* **127**, 419-431. doi:10.1016/j.nbd.2019.03.026
- Kirchhausen, T., Owen, D. J. and Harrison, S. C.** (2014). Molecular structure, function, and dynamics of clathrin-mediated membrane traffic. *Cold Spring Harb. Perspect. Biol.* **6**, a016725. doi:10.1101/cshperspect.a016725
- La Fontaine, S. and Mercer, J. F. B.** (2007). Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. *Arch. Biochem. Biophys.* **463**, 149-167. doi:10.1016/j.abb.2007.04.021
- Li, W., Puertollano, R., Bonifacino, J. S., Overbeek, P. A. and Everett, E. T.** (2010). Disruption of the murine Ap2 β 1 gene causes nonsyndromic cleft palate. *Cleft Palate Craniofac. J.* **47**, 566-573. doi:10.1597/09-145
- Mantegazza, A. R., Guttentag, S. H., El-Benna, J., Sasai, M., Iwasaki, A., Shen, H., Laufer, T. M. and Marks, M. S.** (2012). Adaptor protein-3 in dendritic cells facilitates phagosomal toll-like receptor signaling and antigen presentation to CD4⁺ T cells. *Immunity* **36**, 782-794. doi:10.1016/j.immuni.2012.02.018
- Martinelli, D., Travaglini, L., Drouin, C. A., Ceballos-Picot, I., Rizza, T., Bertini, E., Carrozzo, R., Petri, S., de Lonlay, P., El Hachem, M. et al.** (2013). MEDNIK syndrome: a novel defect of copper metabolism treatable by zinc acetate therapy. *Brain* **136**, 872-881. doi:10.1093/brain/awt012
- Matsuda, S., Miura, E., Matsuda, K., Kakegawa, W., Kohda, K., Watanabe, M. and Yuzaki, M.** (2008). Accumulation of AMPA receptors in autophagosomes in neuronal axons lacking adaptor protein AP-4. *Neuron* **57**, 730-745. doi:10.1016/j.neuron.2008.02.012
- Mattera, R., Park, S. Y., De Pace, R., Guardia, C. M. and Bonifacino, J. S.** (2017). AP-4 mediates export of ATG9A from the trans-Golgi network to promote autophagosome formation. *Proc. Natl. Acad. Sci. USA* **114**, E10697-E10706. doi:10.1073/pnas.1717327114
- Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., Füllgrabe, J., Jackson, A., Jimenez Sanchez, M., Karabiyik, C. et al.** (2017). Autophagy and neurodegeneration: pathogenic mechanisms and therapeutic opportunities. *Neuron* **93**, 1015-1034. doi:10.1016/j.neuron.2017.01.022
- Mettlen, M. and Danuser, G.** (2014). Imaging and modeling the dynamics of clathrin-mediated endocytosis. *Cold Spring Harb. Perspect. Biol.* **6**, a017038. doi:10.1101/cshperspect.a017038
- Meyer, C., Zizioli, D., Lausmann, S., Eskelinen, E.-L., Hamann, J., Saftig, P., von Figura, K. and Schu, P.** (2000). μ 1A-adaptin-deficient mice: lethality, loss of AP-1 binding and rerouting of mannose 6-phosphate receptors. *EMBO J.* **19**, 2193-2203. doi:10.1093/emboj/19.10.2193
- Meyer, K., Kirchner, M., Uyar, B., Cheng, J.-Y., Russo, G., Hernandez-Miranda, L. R., Szymborska, A., Zauber, H., Rudolph, I. M., Willnow, T. E. et al.** (2018). Mutations in disordered regions can cause disease by creating dileucine motifs. *Cell* **175**, 239-253.e17. doi:10.1016/j.cell.2018.08.019
- Mishra, S. K., Keyel, P. A., Hawryluk, M. J., Agostinelli, N. R., Watkins, S. C. and Traub, L. M.** (2002a). Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor. *EMBO J.* **21**, 4915-4926. doi:10.1093/emboj/cdf487
- Mishra, S. K., Watkins, S. C. and Traub, L. M.** (2002b). The autosomal recessive hypercholesterolemia (ARH) protein interfaces directly with the clathrin-coat machinery. *Proc. Natl. Acad. Sci. USA* **99**, 16099-16104. doi:10.1073/pnas.252630799
- Mitsunari, T., Nakatsu, F., Shioda, N., Love, P. E., Grinberg, A., Bonifacino, J. S. and Ohno, H.** (2005). Clathrin adaptor AP-2 is essential for early embryonic development. *Mol. Cell Biol.* **25**, 9318-9323. doi:10.1128/MCB.25.21.9318-9323.2005
- Montpetit, A., Côté, S., Brustein, E., Drouin, C. A., Lapointe, L., Boudreau, M., Meloche, C., Drouin, R., Hudson, T. J., Drapeau, P. et al.** (2008). Disruption of AP1S1, causing a novel neurocutaneous syndrome, perturbs development of the skin and spinal cord. *PLoS Genet.* **4**, e1000296. doi:10.1371/journal.pgen.1000296
- Nakatsu, F., Okada, M., Mori, F., Kumazawa, N., Iwasa, H., Zhu, G., Kasagi, Y., Kamiya, H., Harada, A., Nishimura, K. et al.** (2004). Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. *J. Cell Biol.* **167**, 293-302. doi:10.1083/jcb.200405032
- Nesbit, M. A., Hannan, F. M., Howles, S. A., Babinsky, V. N., Head, R. A., Cranston, T., Rust, N., Hobbs, M. R., Heath, H. R. and Thakker, R. V.** (2013a). Mutations affecting G-protein subunit α 11 in hypercalcaemia and hypocalcaemia. *N. Engl. J. Med.* **368**, 2476-2486. doi:10.1056/NEJMoa1300253
- Nesbit, M. A., Hannan, F. M., Howles, S. A., Reed, A. A. C., Cranston, T., Thakker, C. E., Gregory, L., Rimmer, A. J., Rust, N., Graham, U. et al.** (2013b). Mutations in AP2S1 cause familial hypocalcaemic hypercalcaemia type 3. *Nat. Genet.* **45**, 93-97. doi:10.1038/ng.2492
- Ohno, H., Stewart, J., Fournier, M. C., Bosshart, H., Rhee, I., Miyatake, S., Saito, T., Gallusser, A., Kirchhausen, T. and Bonifacino, J. S.** (1995). Interaction of tyrosine-based sorting signals with clathrin-associated proteins. *Science* **269**, 1872-1875. doi:10.1126/science.7569928
- Owen, D. J. and Evans, P. R.** (1998). A structural explanation for the recognition of tyrosine-based endocytotic signals. *Science* **282**, 1327-1332. doi:10.1126/science.282.5392.1327
- Pearse, B. M. F. and Robinson, M. S.** (1984). Purification and properties of 100-kD proteins from coated vesicles and their reconstitution with clathrin. *EMBO J.* **3**, 1951-1957. doi:10.1002/j.1460-2075.1984.tb02075.x
- Peden, A. A., Oorschot, V., Hesser, B. A., Austin, C. D., Scheller, R. H. and Klumperman, J.** (2004). Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. *J. Cell Biol.* **164**, 1065-1076. doi:10.1083/jcb.200311064
- Peden, A. A., Rudge, R. E., Lui, W. W. Y. and Robinson, M. S.** (2002). Assembly and function of AP-3 complexes in cells expressing mutant subunits. *J. Cell Biol.* **156**, 327-336. doi:10.1083/jcb.200107140
- Pensato, V., Castellotti, B., Gellera, C., Pareyson, D., Ciano, C., Nanetti, L., Salsano, E., Piscosquito, G., Sarto, E., Eoli, M. et al.** (2014). Overlapping phenotypes in complex spastic paraplegias SPG11, SPG15, SPG35 and SPG48. *Brain* **137**, 1907-1920. doi:10.1093/brain/awu121
- Ren, X., Farias, G. G., Canagarajah, B. J., Bonifacino, J. S. and Hurley, J. H.** (2013). Structural basis for recruitment and activation of the AP-1 clathrin adaptor complex by Arf1. *Cell* **152**, 755-767. doi:10.1016/j.cell.2012.12.042
- Reusch, U., Bernard, O., Koszinowski, U. and Schu, P.** (2001). AP-1A and AP-3A lysosomal sorting functions. *Traffic* **3**, 752-761. doi:10.1034/j.1600-0854.2002.31007.x
- Robinson, M. S.** (2015). Forty years of clathrin-coated vesicles. *Traffic* **16**, 1210-1238. doi:10.1111/tra.12335
- Robinson, M. S. and Bonifacino, J. S.** (2001). Adaptor-related proteins. *Curr. Opin. Cell Biol.* **13**, 444-453. doi:10.1016/S0955-0674(00)00235-0
- Seong, E., Wainer, B. H., Hughes, E. D., Saunders, T. L., Burmeister, M. and Faundez, V.** (2005). Genetic analysis of the neuronal and ubiquitous AP-3 adaptor complexes reveals divergent functions in brain. *Mol. Biol. Cell* **16**, 128-140. doi:10.1091/mbc.e04-10-0892
- Setta-Kaffetzki, N., Simpson, M. A., Navarini, A. A., Patel, V. M., Lu, H.-C., Allen, M. H., Duckworth, M., Bachelez, H., Burden, A. D., Choon, S.-E. et al.** (2014). AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. *Am. J. Hum. Genet.* **94**, 790-797. doi:10.1016/j.ajhg.2014.04.005
- Simpson, F., Peden, A. A., Christopoulou, L. and Robinson, M. S.** (1997). Characterization of the adaptor-related protein complex, AP-3. *J. Cell Biol.* **137**, 835-845. doi:10.1083/jcb.137.4.835

- Sitaram, A., Dennis, M. K., Chaudhuri, R., De Jesus-Rojas, W., Tenza, D., Setty, S. R. G., Wood, C. S., Sviderskaya, E. V., Bennett, D. C., Raposo, G. et al. (2012). Differential recognition of a dileucine-based sorting signal by AP-1 and AP-3 reveals a requirement for both BLOC-1 and AP-3 in delivery of OCA2 to melanosomes. *Mol. Biol. Cell* **23**, 3178-3192. doi:10.1091/mbc.e11-06-0509
- Slabicki, M., Theis, M., Krastev, D. B., Samsonov, S., Mundwiler, E., Junqueira, M., Paszkowski-Rogacz, M., Teyra, J., Heninger, A.-K., Poser, I. et al. (2010). A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. *PLoS Biol.* **8**, e1000408. doi:10.1371/journal.pbio.1000408
- Stachowiak, J. C., Schmid, E. M., Ryan, C. J., Ann, H. S., Sasaki, D. Y., Sherman, M. B., Geissler, P. L., Fletcher, D. A. and Hayden, C. C. (2012). Membrane bending by protein-protein crowding. *Nat. Cell Biol.* **14**, 944-949. doi:10.1038/ncb2561
- Stagg, S. M., Gürkan, C., Fowler, D. M., LaPointe, P., Foss, T. R., Potter, C. S., Carragher, B. and Balch, W. E. (2006). Structure of the Sec13/31 COPII coat cage. *Nature* **493**, 234-238. doi:10.1038/nature04339
- Takahashi, D., Hase, K., Kimura, S., Nakatsu, F., Ohmae, M., Mandai, Y., Sato, T., Date, Y., Ebisawa, M., Kato, T. et al. (2011). The epithelia-specific membrane trafficking factor AP-1B controls gut immune homeostasis in mice. *Gastroenterology* **141**, 621-632. doi:10.1053/j.gastro.2011.04.056
- Tarpey, P. S., Stevens, C., Teague, J., Edkins, S., O'Meara, S., Avis, T., Barthorpe, S., Buck, G., Butler, A., Cole, J. et al. (2006). Mutations in the gene encoding the sigma 2 subunit of the adaptor protein 1 complex, AP1S2, cause X-linked mental retardation. *Am. J. Hum. Genet.* **79**, 1119-1124. doi:10.1086/510137
- Theos, A. C., Tenza, D., Martina, J. A., Hurbain, I., Peden, A. A., Sviderskaya, E. V., Stewart, A., Robinson, M. S., Bennett, D. C., Cutler, D. F. et al. (2005). Functions of adaptor protein (AP)-3 and AP-1 in tyrosinase sorting from endosomes to melanosomes. *Mol. Biol. Cell* **16**, 5356-5372. doi:10.1091/mbc.e05-07-0626
- Traub, L. M. (2009). Tickets to ride: selecting cargo for clathrin-regulated internalization. *Nat. Rev. Mol. Cell Biol.* **10**, 583-596. doi:10.1038/nrm2751
- Traub, L. M. and Bonifacino, J. S. (2013). Cargo recognition in clathrin-mediated endocytosis. *Cold Spring Harb. Perspect. Biol.* **5**, a016790. doi:10.1101/cshperspect.a016790
- Verkerk, A. J. M. H., Schot, R., Dumeé, B., Schellekens, K., Swagemakers, S., Bertoli-Avella, A. M., Lequin, M. H., Dudink, J., Govaert, P., van Zwol, A. L. et al. (2009). Mutation in the AP4M1 gene provides a model for neuroaxonal injury in cerebral palsy. *Am. J. Hum. Genet.* **85**, 40-52. doi:10.1016/j.ajhg.2009.06.004
- Yamaguchi, J., Suzuki, C., Nanao, T., Kakuta, S., Ozawa, K., Tanida, I., Saitoh, T., Sunabori, T., Komatsu, M., Tanaka, K. et al. (2018). Atg9a deficiency causes axon-specific lesions including neuronal circuit dysgenesis. *Autophagy* **14**, 764-777. doi:10.1080/15548627.2017.1314897
- Yi, L. and Kaler, S. G. (2015). Direct interactions of adaptor protein complexes 1 and 2 with the copper transporter ATP7A mediate its anterograde and retrograde trafficking. *Hum. Mol. Genet.* **24**, 2411-2425. doi:10.1093/hmg/ddv002
- Zaremba, S. and Keen, J. H. (1983). Assembly polypeptides from coated vesicles mediate reassembly of unique clathrin coats. *J. Cell Biol.* **97**, 1339-1347. doi:10.1083/jcb.97.5.1339
- Zizioli, D., Meyer, C., Guhde, G., Saftig, P., von Figura, K. and Schu, P. (1999). Early embryonic death of mice deficient in γ -adaptin. *J. Biol. Chem.* **274**, 5385-5390. doi:10.1074/jbc.274.9.5385